Malignant hyperthermia (MH) is a pharmacogenetic condition whereby in susceptible individuals, a rapid hypermetabolic response results from skeletal muscle calcium dysregulation 1 . Current studies into MH are limited by the utility of nonhuman skeletal muscle models or human non-skeletal muscle cell lines such as HEK-293 cells 2, 3 . Furthermore, experiments that use primary human tissue are inherently limited because of the rapid onset of replicative senescence that has been observed 4 . Thus, there is a crucial need to develop methods that will extend the life of cells derived from patients who are susceptible to MH (MHS) and their non-susceptible relatives (MHN) in order to allow an improved understanding of the mechanisms that underlie the pathophysiology of the human MH reaction. This study aims to develop such human skeletal muscle cell lines derived from patients with unique mutations associated with MH as well as those from their MHN relatives. Human biopsy samples taken for the diagnostic in vitro contracture tests were processed as previously described to isolate human myoblasts 5 . Myoblasts from three MHS patients, three MHN family members and a non-related MHN individual, were infected using the g-retroviral system to deliver genes encoding CDK-4 (cyclin dependent kinase) and hTERT (human telomerase reverse transcriptase). Successfully infected cells were selected using both puromycin (0.3 mg/ml) and hygromycin (50 mg/ml) for at least two weeks. Cells were then allowed to proliferate to over 10 doublings before undergoing fluorescent activated cell sorting (FACS) for CD56 and CD82 antigens in order to produce monoclonal and polyclonal pure myoblast cell lines. Myoblasts from two MHS patients and four MHN patients survived dual antibiotic selection for at least two weeks. These cells proliferated from approximately 10 000 cells to over one million cells prior to undergoing FACS, following which they were clonally expanded. All immortalised samples were found to contain cells positive for both CD56 and CD82, a combination which has recently been reported to be a marker of myoblasts that are able to differentiate into myotubes 6 .
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The immortalisation of these six primary human samples from MHS and MHN patients is novel the best of our knowledge. The cells are currently undergoing further characterisation in order to produce a regenerative pool of cells that will have the ability to replicate by more than 100 doublings and potentially providing over 1 Malignant hyperthermia (MH) is a progressive hypermetabolic reaction that occurs in genetically susceptible patients in response to triggering anaesthetic agents: the inhalation anaesthetics and the depolarizing muscle relaxant, succinylcholine. Index cases may be referred for testing because they developed features suggestive of a hypermetabolic MH reaction: a severe hypermetabolic reaction can progress to muscle rigidity and rhabdomyolysis. Other index cases are referred because they developed exaggerated muscle rigidity following succinylcholine or unexplained postoperative rhabdomyolysis, both of which are more common in individuals who are susceptible to MH. Our main aim was to identify the effect of the use of different anaesthetic drugs on the development of variable clinical features of MH. We included MH probands who were tested susceptible to MH using the in vitro contracture test (IVCT) between 1988 and 2017. Data were collected from copies of anaesthetic and perioperative records (where available), referral letters and copies of laboratory test results stored in the Leeds MH unit archive. We recorded the patient's age, sex, medical and anaesthetic history, details of drugs administered during anaesthesia, and the timing, nature and severity of clinical features associated with MH.
We collected data on 343 index cases, while 23 patients were excluded because of insufficient information. The mean age-at-episode of the included 320 patients was 24 years (range 2e74) and 66.9% (214 of 320) were males. In our cohort, 119 patients presented with both metabolic and muscular manifestations, 155 patients with hypermetabolic manifestations only and 46 patients presented with muscular rigidity. The reaction was triggered by both succinylcholine and inhalation agents in 171 patients, succinylcholine only in 53 patients and inhalation anaesthetics only in 96 patients.
Non-depolarising muscle relaxants (NDMR) were used in 95 patients and its use was associated with a statistically significant lower creatine kinase level, nevertheless, no significant effect of the use of NDMR on reducing the incidence of myoglobinuria or generalised muscular rigidity could be noticed. Four patients who received succinylcholine but no inhalational agent developed one or more features possibly suggesting a hypermetabolic MH reaction but alternative causes cannot be excluded because of a lack of information.
Abstracts -e23
The combination of succinylcholine and inhalation anaesthetics led to more severe MH reactions with both muscular and metabolic manifestations. The role of succinylcholine alone in triggering a hypermetabolic MH reaction remains controversial. NDMR reduce the severity of some manifestations of MH but does not protect against the development of a reaction in a susceptible patient.
Development of a Core Outcome Set for studies evaluating the effects of anaesthesia on perioperative morbidity and mortality within the hip fracture population Perioperative studies on hip fracture patients show a large degree of inconsistency in the outcomes they report and how these are defined. The objective was to develop a core outcome set for use in future perioperative hip fracture studies. This would improve the body of comparable evidence when evaluating interventions that affect patient care. 1 A systematic review of literature published between 2000 and 2015 identified all reported outcomes in perioperative hip fracture studies in the context of comparing one type of anaesthesia with another. From this, a list was compiled grouping similar outcomes together and removing duplicates. These outcomes were circulated within the first round of the Delphi questionnaire. Participants were asked to rate the importance of each outcome on a scale of 1 to 9 and suggest additional outcomes. A second round of Delphi provided feedback results and asked participants to rescore each outcome. This process was repeated in a third round of Delphi. Consensus that an outcome should be considered for inclusion at each stage was a score of 7 to 9 by 70% or more participants and a score of 1 to 3 by 30% or fewer participants. Participants represented seven major stakeholder groups globally including anaesthetists, orthopaedic surgeons, orthogeriatricians, nursing staff, physiotherapists, occupational therapists and patients. During two consensus webinars, each outcome and their inclusion in a final core outcome set was discussed at length.
The first round questionnaire contained 34 discrete outcomes obtained from a systematic review of the literature. Participants proposed an additional 98 outcomes during this round, the majority of which were similar and were re-categorised into four new outcomes. Thirty eight outcomes were entered for rounds 2 and 3. The number of participants completing rounds 1 to 3 were 242, 186 and 169 respectively. This represented a completion rate of 70%. Seventeen outcomes ranked critical by the Delphi panel were considered at two consensus webinars. Outcomes included from these were: mortality, time from injury to surgery, orthogeriatric input, delirium, acute coronary syndrome, acute kidney injury, hypotension, pain, out of bed at day 1, sepsis and pneumonia. They were categorised into domains representing true patient outcomes and processes of care deemed to be of importance.
We used robust consensus methodology to develop the first core outcome set for use in studies evaluating the effects of anaesthesia perioperatively in the hip fracture population. We recommend this set is used as a minimum number of outcomes reported in future studies in order to facilitate pooling of data and better comparisons between studies. Of 194 responders, 96% practice in the UK and 84.5% are anaesthetic/ICU consultants. There is a marked divergence in perioperative practice as to whether either drug class should be continued/stopped (Fig. 7) . Postoperatively, a systolic blood pressure of 90 mmHg in a stable patient would not deter 10% of clinicians from restarting the ACEi/ARBs if this represented their usual practice.
The preoperative scenarios revealed that if a patient was acutely hypertensive on the day of surgery, the decision to proceed had no correlation with clinician preference to stopping or continuing ACEi/ARBs (Odds Ratio: 1.19 (95% confidence interval:0.60e2.37)). Faced with acute hypertension and myocardial injury within 24 hours after surgery, only 57% of clinicians, who would routinely restart normal ACEi/ARB therapy with 24 hours, would use these drugs in this scenario (Odds Ratio: 0.86 (95% confidence interval 0.43e1.69)).
This survey provides support that a mechanistic trial such as SPACE is essential. Seeing such a variation in clinical practice with regards to pre-and post-operative management of ACEi and ARBs highlights the need for clear evidence based guidelines.
